D3 Dopamine Receptor Allosteric Modulators for Selective CNS Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dopaminergic drugs lack selectivity between D2 and D3 dopamine receptors, leading to off-target side effects and limited therapeutic efficacy in treating conditions like substance use disorder and Parkinson's disease.
Innovation Solution
Development of highly selective D3 dopamine receptor (D3 DAR)-selective negative allosteric modulators (NAMs) that bind to an allosteric site, reducing cross-reactivity with D2 DARs and minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orthosteric binding site ligands are used to target dopamine receptors, then therapeutic efficacy is achieved, but selectivity between D2 and D3 receptors is lost leading to off-target side effects
Solution Approach 1:
The patent transitions from orthosteric binding (one-dimensional competition at the primary binding site) to allosteric modulation (binding at a different spatial dimension/location on the receptor). This dimensional shift allows the compound to modulate D3 receptor activity without competing for the conserved orthosteric binding site, thereby achieving selectivity while maintaining therapeutic efficacy.
Solution Approach 2:
The invention exploits local structural differences in the allosteric binding site between D2 and D3 receptors. By designing ligands that specifically interact with unique amino acid residues in the D3 allosteric site (such as His140, Ser193, Thr197), the compound achieves localized selectivity while the rest of the receptor structure remains modulated therapeutically.
2Adaptability or versatility
If D2 and D3 selective antagonists are developed, then substance use disorder treatment potential increases, but cross-reactivity with other GPCRs creates profound off-target side effects
Solution Approach 1:
The patent uses allosteric binding as a different dimensional approach compared to traditional orthosteric antagonists. This allows the compound to achieve D3 selectivity without the cross-reactivity issues that plague orthosteric ligands, expanding therapeutic potential while reducing off-target effects.
Solution Approach 2:
The invention changes the binding mode parameter from competitive orthosteric binding to non-competitive allosteric modulation. This parameter change fundamentally alters the selectivity profile, allowing high D3 affinity while minimizing interactions with other GPCR families, thus reducing off-target side effects.
3Reliability
If high affinity D3 DAR-selective antagonists are designed, then attenuation of heroin self-administration is achieved, but complexity of achieving selectivity over D2 DAR increases
Solution Approach 1:
The patent uses the allosteric site as an intermediary binding location that provides inherent selectivity. By binding at this intermediate location rather than directly competing for the orthosteric site, the ligand achieves D3 selectivity through the unique structural features of the allosteric pocket, simplifying the design process compared to attempting to optimize orthosteric binding selectivity.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A
AI summary
Compounds of Formula I, Formula II, and Formula III and the pharmaceutically acceptable salts thereof are disclosed. The variables R1-10 are disclosed herein. The compounds are useful for treating central nervous system disorders, especially those involving substance use disorder and/or withdrawal syndrome. Pharmaceutical compositions containing compounds of Formula I or Formula II or Formula III and methods of treatment comprising administering compounds of Formula I or Formula II or Formula III are also disclosed.